Rezenopy is a drug owned by Scienture Llc. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 05, 2041. Details of Rezenopy's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12514854 | Drug Products For Intranasal Administration And Uses Thereof |
Feb, 2041
(14 years from now) | Active |
FDA has granted several exclusivities to Rezenopy. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Rezenopy, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Rezenopy.
Exclusivity Information
Rezenopy holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Rezenopy's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 19, 2027 |
US patents provide insights into the exclusivity only within the United States, but
Rezenopy is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Rezenopy's family patents as well as insights into
ongoing legal events
on those patents.
Rezenopy's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Rezenopy's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 05, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Rezenopy Generic API suppliers:
Naloxone Hydrochloride is the generic name for the brand Rezenopy. 29 different companies have already filed for the generic of Rezenopy, with Igi Labs Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Rezenopy's generic
Alternative Brands for Rezenopy
There are several other brand drugs using the same active ingredient (Naloxone Hydrochloride) as Rezenopy. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Bdsi |
| |||
| Edenbridge Pharms |
| |||
| Emergent |
| |||
| Harm Reduction Therp |
| |||
| Hikma |
| |||
| Indivior |
| |||
| Kaleo Inc |
| |||
| Purdue Pharma Lp |
| |||
| Zmi Pharma |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Naloxone Hydrochloride, Rezenopy's active ingredient. Check the complete list of approved generic manufacturers for Rezenopy
About Rezenopy
Rezenopy is a drug owned by Scienture Llc. Rezenopy uses Naloxone Hydrochloride as an active ingredient. Rezenopy was launched by Scienture in 2024.
Approval Date:
Rezenopy was approved by FDA for market use on 19 April, 2024.
Active Ingredient:
Rezenopy uses Naloxone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Naloxone Hydrochloride ingredient
Dosage:
Rezenopy is available in spray form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG/SPRAY | SPRAY | Prescription | NASAL |